sEH inhibition can augment bradykinin-induced vasodilation in human resistance vessels both in vitro and in vivo, suggesting that sEH inhibition may be a novel therapeutic target to ameliorate cardiovascular risk in patients with smoking-related endothelial dysfunction. The gene discussed is EPHX2; the disease is endothelial dysfunction.